Swiss Biopharma Company Selects Brickell For New U.S. Headquarters
Swiss biopharmaceutical company MoonLake Immunotherapeutics has signed an approximately 11-year lease for 13,500 square feet of office space at Brickell Key Centre II, located at 601 Brickell Key Drive in Miami. The transaction, reported in November 2026, establishes a new U.S. headquarters for the Switzerland-based biotechnology company, which plans to employ approximately 75 people in the Miami area. The office is expected to open during the first quarter of 2027, adding an international life sciences tenant to one of South Florida’s most prominent business districts.
Swiss Biopharma Company Expands U.S. Presence
Headquartered in Zug, Switzerland, MoonLake Immunotherapeutics develops treatments for inflammatory diseases affecting the skin and joints. The company is advancing innovative therapies targeting conditions with significant unmet medical needs.
The new Brickell Key headquarters will provide a base for MoonLake’s growing U.S. operations as the company advances its clinical development and commercialization objectives.
Jorge Santos da Silva, CEO of MoonLake Immunotherapeutics, is identified in reporting on the transaction.
The company’s plans for approximately 75 Miami-area employees represent a meaningful commitment to establishing a permanent operational presence in South Florida.
Brickell Key Attracts International Corporate Tenant
Brickell Key Centre II is situated on Brickell Key, an island business and residential community adjacent to Miami’s Brickell financial district.
The location provides access to Miami’s concentration of international businesses, financial institutions and professional service firms.
MoonLake’s decision to establish its U.S. headquarters in the district also illustrates Brickell’s appeal beyond its traditional base of financial services and related corporate tenants.
Long-Term Lease Reflects Commitment to Miami
With an approximately 11-year lease, MoonLake is making a substantial long-term commitment to the Miami office market.
The transaction is notable for both its duration and the tenant’s industry. Biotechnology and pharmaceutical businesses can bring specialized employment opportunities and diversify the mix of companies occupying Class A office properties.
For South Florida’s commercial real estate market, the lease demonstrates how international companies establishing U.S. operations can contribute to office absorption. It also highlights the potential for growth-oriented life sciences businesses to consider Miami as a corporate headquarters location, even when their research and development activities may be conducted elsewhere.
Key Facts
- Property: Brickell Key Centre II
- Location: 601 Brickell Key Drive, Miami, FL
- Asset Type: Office
- Transaction Type: Office lease for new U.S. headquarters
- Tenant: MoonLake Immunotherapeutics
- Size: 13,500 SF
- Lease Term: Approximately 11 years
- Reported Transaction Date: November 9, 2026
- Expected Opening: First quarter 2027
- Planned Employment: Approximately 75 Miami-area employees
- Other Notable Details: U.S. headquarters for Zug, Switzerland-based biopharmaceutical company
Source: Traded
